• Nutriband posted a net loss of $8.23 million for fiscal year ended Jan. 31, 2026, narrowing from a loss of $10.48 million a year earlier.
• Revenue slipped 4.81% to $2.04 million.
• Gross profit fell 23.8% to $566,308, due primarily to lower margins on tape sales.
• Pocono Pharmaceuticals generated all revenue, while 4P Therapeutics recorded no revenue as its main contract wound down in the prior year.
• Management expects increased demand in the subsequent year and said it believes sufficient funds will be generated from operations to fund operations for one year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-049399), on April 29, 2026, and is solely responsible for the information contained therein.